Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

Abstract Background Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor volume via intratumoral accumulation of CD8+ T cells. We hypothesized t...

Full description

Bibliographic Details
Main Authors: Matthew J. Reilley, Ann Bailey, Vivek Subbiah, Filip Janku, Aung Naing, Gerald Falchook, Daniel Karp, Sarina Piha-Paul, Apostolia Tsimberidou, Siqing Fu, JoAnn Lim, Stacie Bean, Allison Bass, Sandra Montez, Luis Vence, Padmanee Sharma, James Allison, Funda Meric-Bernstam, David S. Hong
Format: Article
Language:English
Published: BMJ Publishing Group 2017-04-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Melanoma
Imatinib
Maximum Toxic Dose
Dasatinib
Ipilimumab
Online Access:http://link.springer.com/article/10.1186/s40425-017-0238-1

Internet

http://link.springer.com/article/10.1186/s40425-017-0238-1

Similar Items